Date/Time: Sunday, September 10, 2023 - 7:30 PM – 8:30 PM
Track: Satellite Symposia
Room: Franklin Hall 2 (4th Floor)
Log in to Add to My Schedule

Description:

Sponsored by Eisai

With the advent of disease-modifying treatments (DMTs) for patients with early Alzheimer’s disease, neurologists will encounter new queries from patients, their family, and care partners in primary and secondary care settings. Please join us as two prominent clinical experts in the field of Alzheimer’s disease provide their insights on the evolving diagnostic and treatment landscape. The speakers will give their perspectives on several topics including: changes in the diagnostic workflow utilizing traditional and novel clinical tools; implementation of biomarkers to aid in AD diagnosis; patient appropriateness for potential disease-modifying treatments; managing patient expectations; and treatment outcomes and appropriate monitoring. This session will provide case-based examples of patient profiles and will highlight the perspective of clinicians, as well as patients, including those who are considering disease-modifying treatments as potential therapeutic options. Additionally, the speakers will discuss the benefits and risks associated with DMTs. This session aims to provide insights for general neurologists that may be helpful for the clinical management of patients with Alzheimer’s disease and assist in the feasible implementation of new treatments.

Speakers:

Darren Gitelman, MD, FAAN, FANA

Director of Cognitive Disorders, Advocate Medical Group

Neurosciences Medical Research Director

Senior Medical Director, Advocate Memory Center

Advocate Lutheran General Hospital

Chicago, IL  

Jessica Zwerling, MD, MS

Director, Montefiore Hudson Valley Center of Excellence for Alzheimer's Disease (CEAD)

Professor of Neurology, Albert Einstein College of Medicine

New York, NY